SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-119591
Filing Date
2021-09-27
Accepted
2021-09-27 08:57:51
Documents
14
Period of Report
2021-09-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2128472d1_8k.htm   iXBRL 8-K 40644
2 EXHIBIT 4.1 tm2128472d1_ex4-1.htm EX-4.1 110096
3 EXHIBIT 10.1 tm2128472d1_ex10-1.htm EX-10.1 257719
  Complete submission text file 0001104659-21-119591.txt   670776

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20210924.xsd EX-101.SCH 3186
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20210924_lab.xml EX-101.LAB 34594
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20210924_pre.xml EX-101.PRE 22711
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2128472d1_8k_htm.xml XML 3636
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 211279107
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences